Another project by Deep Patterns LLC has successfully passed the Skolkovo foundation expertise. This time the project named “DP4SAR – innovative tool for discovering patterns in chemical structures and structure - activity relationships for directed drug design...
Preclinical efficacy study results for the first Russian humanised monoclonal antibody OM-RCA-01, indicated for treatment of renal cell carcinoma, were presented at the New Technologies session of the Congress of the American Society of Clinical Oncology (ASCO...
SQ109 will be evaluated for efficacy on multi-drug resistant patients Sequella, a clinical-stage pharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, licensed the late-stage development and commercialization...
On June 29, the Federal Service on Intellectual Property Rospatent published a list of 100 best inventions in Russia in 2011, which included patent No. 2435783 “Chimeric peptide and it’s pharmaceutical composition for cancer disease treatment”...
The second annual awarding ceremony of Investor Awards 2012 winners took place on May 23 in Moscow after the end of the forum Invest in Russia. The investment round in the innovative biotechnological company OncoMax, that received investments from Maxwell Biotech...
On November 17-18, the IV international “Life Sciences Invest. Partnering Russia” partnering forum will be held at Talion Imperial Hotel, Saint Petersburg. Prof. Vyacheslav Duke, founder and scientific director of Deep Patterns, LLC, became a member of the...
The XIV international conference “Regional Informatics-2014” will be held on 29-31 of October in Saint-Petersburg. V. Duke, Deep Patterns founder and scientific director will attend the conference as head of “Information technologies in Health Care industry...
Establishes in principle the possibility of developing the evaporative vortex type new climate equipment on the basis of the developed innovation approach to the method of producing cold
On October 30, the “Information technologies in medicine and healthcare” section of XIV international conference “Regional informatics 2014” was held by dr. Vyacheslav Duke, founder and scientific director of Deep Patterns, LLC. The section workshop was attended...
Based on the consideration of applications for participation in an open competition for the government contracts for research and development under the Federal Target Program "Development of the Pharmaceutical and Medical Industry of the Russian Federation...
Specialists of the Scientific and Production Center “Probiotek” complete preclinical studies of the innovative non-narcotic analgesic “Anodinol®”, intended for the relief of moderate or moderately severe pain: pharmvestnik.ru/.../Zavershautsya-doklinicheskie...
The report "The possibility to use the epithelial carcinoma marker CA-62 for the early detection of malignant epithelial tumors" during Skolkovo session headed by the Academician Alexander G. Rumyantsev was done in Russian Oncological Congress by...
Currently the Center is in the process of reorganization. Project execution temporarily suspended. We apologize.
Alyzea LLC have started a campaign at the one of the most known crowdfunding platforms Indiegogo. Everyone is welcome to participate and back us: igg.me/.../19927668javascript:void(0)
More information and sign-up here: www.indiegogo.com/.../19927668
In December 2017, IPHARMA received four approvals from the Ministry of health of the Russian Federation to conduct clinical trials. And, according to the results of 2017 (15 approvals), entered the TOP-3 CROs. - BE study of Aberon (abiraterone acetate) ...
The Quality Assurance Forum began its work in June 2017. This Forum assembled quality assurance experts in pharmaceutical industry for the exchange of experience and mutual support. The first meeting of the Forum participants will be held on December 14...
On November 14-15, the 6th International Forum "Clinical trials in Russia" of the Adam Smith Institute was held in Moscow. IPHARMA was one of the major sponsors of the conference. This year, a large pool of interesting speakers including representatives...
On November 14-16, XXI Russian Oncology Congress passed in Moscow. It is one of the largest international events in the field of oncology, in which more than 5,000 doctors take part annually. Permanent organizers of the congress: N.N. Blokhin Russian...
In early November, IPHARMA received two approvals from the Ministry of Health of the Russian Federation to conduct phase I clinical trials of Ventvil® and Slavinorm® medicinal products. Protocol № HEP-VTL-01 "A double-blind, randomized, placebo...
Российская Федерации и Республика Индия давно ведут собственные проекты по внедрению и эксплуатации телемедицинских систем. Особенно активизировались эти работы в последние годы, когда Правительства обеих стран стали уделять серьезное внимание переходу к цифровому...
On November 14-15 the sixth international conference of the Adam Smith Institute "Clinical Research in Russia" will be held . IPHARMA is one of the sponsors of the conference. Under the program the latest regulatory changes, update the ICH GCP...
On October, 30 IPHARMA received the Ministry of Health permission to conduct Phase I trial of Hondrolux®. Protocol № ОА-CLX-01 “Double-blind, randomized, placebo-controlled study to access safety and tolerability of single and following multiple...
New article had been pubblished in MedCrave Ivaniuk Natallia, Ponimash Zahar, Karimov Vladimir "Control Systems of Bionic Limbs of the New Generation" Citation: Natallia I, Zahar P, Vladimir K (2017) Control Systems of Bionic Limbs of the New Generation...
Adaptive design is an innovative approach that allows to conduct clinical trials more efficiently (with fewer patients, in shorter terms) or to increase the likelihood of demonstrating the effect of the drug. In studies with adaptation, the possibility of modifying...